If you've tried to hire an experienced regulatory affairs specialist or clinical project manager in the past 12 months, you already know the market is tight. What you may not fully appreciate is how structural this shortage has become, and why smaller biotechs and CROs need to rethink their approach to compete for the best talent.

The scale of the problem

Demand for clinical and regulatory professionals is rising faster than supply across pharma, biotech, medtech, and CROs. These roles sit at the intersection of science, compliance, and patient safety. They require deep technical expertise, strong judgement, and the ability to navigate evolving global regulatory frameworks. Unlike some functions, they cannot be scaled quickly or replaced through automation.

Several forces are making the crunch worse. Regulatory complexity continues to increase, driven by new frameworks like the EU Pharma Package, the UK's clinical trials regulations overhaul (came into force 28 April 2026), and Health Canada's proposed new framework. Growth in advanced therapies, including cell and gene therapies, demands highly specialised expertise that takes years to develop. The talent pipeline has long lead times. And high attrition means experienced professionals are constantly being recruited away by competitors.

Where the pain is greatest

The pressure is most acute in several areas: Clinical Project Management and Clinical Operations, Regulatory Affairs (CMC, global submissions, labelling, and post-approval), Quality Assurance and Compliance, Pharmacovigilance and Drug Safety, and Medical Affairs and Clinical Science.

These roles are not just nice-to-haves. Gaps in expertise directly impact development timelines, regulatory approvals, and ultimately market access. For smaller companies, a single unfilled regulatory affairs role can stall an entire submission programme.

What leading organisations are doing differently

The companies successfully navigating this crunch are taking a more flexible approach to recruitment. They are broadening search criteria, focusing on core competencies and regulatory exposure rather than identical role histories. 

They are considering adjacent experience, such as candidates transitioning from CROs to sponsors, from regional to global roles, or from one therapeutic area to another, where the regulatory principles translate. Larger companies are aligning hiring managers early to clarify what is truly essential versus what is desirable, reducing the risk of searching for candidates who simply do not exist.

This matters particularly for smaller biotechs and CROs that may not have the brand recognition of a large pharma company. In a constrained talent market, relying solely on reactive hiring or narrow candidate profiles means missing out on strong professionals who could excel with the right support and onboarding.

Employer brand also plays a significant role. Clinical and regulatory professionals are typically risk-aware, highly selective, and motivated by stability, scientific credibility, and long-term career impact. Organisations that clearly communicate their commitment to quality, the scientific value of their work, and genuine opportunities for progression have a measurable advantage in attracting passive candidates.

The recruiter's perspective

From our vantage point, the organisations losing in this market are those that take too long to make decisions. Extended hiring processes increase the risk of losing candidates to competing offers, particularly when the strongest candidates have multiple options.

Best-in-class hiring processes in this space are structured and transparent, with clearly defined stages. They are technically credible, with interviewers who understand the regulatory and clinical context. The companies that move from first interview to offer within two to three weeks are consistently landing the best talent.

Equally important is retention. Given the scarcity of experienced professionals, keeping your existing team is as critical as recruiting new talent. Clear role scope, realistic expectations, support for continued professional development, and opportunities to work on varied or global programmes all contribute to longer tenure.

For TA and HR leaders at small to mid-sized Life Sciences companies, the message is straightforward. The skills crunch is not easing. But organisations that adapt their recruitment strategies, move quickly, and invest in both attraction and retention can still build strong teams. Partnering with specialist recruiters who understand both the technical and regulatory landscape can help accelerate that process.

If you are experiencing challenges filling clinical or regulatory roles, we would be happy to share what we are seeing in the market and discuss how we can help.